Table 1.
Pre-Randomization Characteristics
| Placebo (n = 5) |
Prednisone (n = 6) |
|
|---|---|---|
|
| ||
| Men, n (%) | 2 (40%) | 4 (67%) |
|
| ||
| Age (years), mean (SD) | 62 (9) | 64 (18) |
|
| ||
| White, n (%) | 4 (80%) | 4 (67%) |
|
| ||
| Disease duration (months), median (range) | 5 (4–17) | 7.5 (1–18) |
|
| ||
| Diagnostic tests, n (%) | ||
| AChR Antibodies | 3 (60%) | 2 (33%) |
| Single fiber EMG | 2 (40%) | 2 (33%) |
| Ice test | 1 (20%) | 3 (50%) |
|
| ||
| Pyridostigmine dosage (mg/day), median (range) | 360 (240–480) | 330 (0–480) |
|
| ||
| Medical history, n (%) | ||
| Impaired glucose tolerance | 2 (40%) | 2 (40%) |
| Diabetes | 0 | 0 |
| Glaucoma | 0 | 0 |
| Cataracts | 3 (60%) | 2 (33%) |
| Osteopenia or osteoporosis | 3 (60%) | 2 (33%) |
|
| ||
| MG-QoL-15 score, median (range) | 3 (0–13) | 6 (2–31) |
|
| ||
| NEI-VFQ-25 score, median (range) | 87 (82–100) | 85 (72–91) |
|
| ||
| NEI-VFQ-25 10-item neuro-ophthalmological supplement score, median (range) | 61 (45–80) | 68 (60–91) |
|
| ||
| Ocular QMG score, median (range) | 6 (3–11) | 6.5 (3–10) |